Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma

Inclusion Criteria

• •patients were required to have a biopsy-proven diagnosis of nasal ENKTL
• •at least 18 years old
• •Ann Arbor stage IE or IIE
• •measurable disease
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• •life expectancy greater than 12 weeks
• •adequate hematologic (hemoglobin \> 9.0 g/dL, absolute neutrophil count \> 1,500/uL and platelets \> 100,000/uL)
• •renal (serum creatinine \< 1.5 mg/dL, creatinine clearance \> 50 mL/min)
• •hepatic (total bilirubin \< 2 times of upper limit of normal and aspartate transferase \< 3 times of upper limit of normal) function
• •Diagnosis of ENKTL is based on the presence of histological features and immunophenotypes compatible with ENKTL (e.g., cytoplasmic CD3+, CD20-, CD56+, positive for cytotoxic molecules, positive for EBV by in situ hybridization).
• •Informed consent